. 2023 Jun 29;22:162. doi: 10.1186/s12933-023-01899-0

Table 2.

Ongoing clinical trials with spironolactone or finerenone in HFpEF.

Drug	Study Name NCT#	Condition / Disease	Estimated/ Actual Enrollment	Primary endpoint	Study start / completion
Spironolactone	SPIRRIT-HFPEF NCT02901184	HFmrEF (EF ≥ 40–49%) + HFpEF (EF ≥ 50%)	2.000	Time to death from any cause	November 2017/ December 2026
Spironolactone	SPIRIT-HF NCT04727073	HFmrEF (EF ≥ 40–49%) + HFpEF (EF ≥ 50%)	1.300	Cumulative number of primary composite events of CV death and total HF hospitalization	November 2018/ December 2024
Finerenone	FINEARTS-HF NCT04435626	HFmrEF (EF ≥ 40–49%) + HFpEF (EF ≥ 50%)	6.016	Number of cardiovascular death and heart failure events	September 2020/ August 2024

Drug

Study Name
NCT#

Condition /
Disease

Estimated/
Actual Enrollment

Primary endpoint

Study start /
completion

Spironolactone

SPIRRIT-HFPEF

NCT02901184

HFmrEF (EF ≥ 40–49%) + HFpEF (EF ≥ 50%)

2.000

Time to death from any cause

November 2017/

December 2026

Spironolactone

SPIRIT-HF

NCT04727073

HFmrEF (EF ≥ 40–49%) + HFpEF (EF ≥ 50%)

1.300

Cumulative number of primary composite events of CV death and total HF hospitalization

November 2018/

December 2024

Finerenone

FINEARTS-HF

NCT04435626

HFmrEF (EF ≥ 40–49%) + HFpEF (EF ≥ 50%)

6.016

Number of cardiovascular death and heart failure events

September 2020/

August 2024

Abbreviations: CV: Cardiovascular, EF: Ejection fraction, HF: Heart failure, HFmrEF: Heart failure with midrange ejection fraction, HFpEF: Heart failure with preserved ejection fraction